Author name: Doug Simpson

Recent paper in Science reaffirms necessity for increased awareness of Lassa virus infections

May 2024 READ THE ARTICLE The article Roberts, L. (Feb 2024). A Spiking Fever… Science, 383 (6685). 810-816, reviews the ongoing global threat from Lassa fever, a deadly hemorrhagic disease endemic in West Africa, which has seen a surge in cases in recent years. The disease, caused by the Lassa virus, is primarily transmitted to […]

Recent paper in Science reaffirms necessity for increased awareness of Lassa virus infections Read More »

Zalgen Immunotherapeutic Confers Complete Protection Against Advanced Multilineage Lassa Infections in Nonhuman Primates

Article in Proceedings of the National Academy of Sciences (PNAS) reports data from the latest study at the University of Texas Medical Branch at Galveston (UTMB) showing protection against Lassa Fever, a significant threat to global health. FREDERICK, Md., Aug. 18, 2023 /PRNewswire/ — Zalgen Labs LLC (Zalgen), a biotechnology and diagnostics company focused on high-impact, neglected infectious diseases, including Lassa Fever (LF), today announced publication

Zalgen Immunotherapeutic Confers Complete Protection Against Advanced Multilineage Lassa Infections in Nonhuman Primates Read More »

Zalgen Licenses Lassa Virus Diagnostic Technology from The Scripps Research Institute

Scripps proprietary glycoprotein technology key to development of new diagnostic tests enabling the design of better, more effective vaccine programs for Lassa fever Zalgen Labs LLC (Zalgen), a biotechnology and diagnostics company focused on high-impact, neglected infectious diseases including Lassa Fever (LF), today announced that it has licensed proprietary technology developed by structural biologist Erica

Zalgen Licenses Lassa Virus Diagnostic Technology from The Scripps Research Institute Read More »

Zalgen Immunotherapeutic Demonstrates 100% Effectiveness Against Advanced Lassa Infections in Non-Human Primates

Article in Nature Medicine reports data from study at the University of Texas Medical Branch at Galveston (UTMB) showing protection against Lassa Fever, a major threat to global health Zalgen Labs LLC (Zalgen), a biotechnology and diagnostics company focused on high-impact, neglected infectious diseases including Lassa Fever (LF), today announced that Arevirumab-3, its lead immunotherapeutic

Zalgen Immunotherapeutic Demonstrates 100% Effectiveness Against Advanced Lassa Infections in Non-Human Primates Read More »

Zalgen Antibodies Used in Solving First Lassa Virus Glycoprotein Trimer Structure

Article in Science provides template for advanced vaccine and immunotherapeutic design against Lassa Fever, a major threat to global health Zalgen Labs LLC (Zalgen), a biotechnology and diagnostics company focused on high-impact, neglected infectious diseases including Lassa Fever (LF), today announced that its human monoclonal antibodies were used in an extensive research collaboration of the

Zalgen Antibodies Used in Solving First Lassa Virus Glycoprotein Trimer Structure Read More »

Zalgen and NOWDiagnostics Announce Strategic Collaboration to Advance Novel Rapid Diagnostic Tests for Tropical Diseases

Collaboration combines Zalgen’s leadership in hemorrhagic fevers and other tropical diseases with NOWDiagnostics’ unique ADEXUSDx® rapid test platform and GMP manufacturing capabilities Zalgen Labs LLC (Zalgen), a biotechnology and diagnostics company focused on high-impact, neglected infectious diseases, announced that it has entered into a series of agreements with NOWDiagnostics Inc. (NOWDx), an innovator in rapid

Zalgen and NOWDiagnostics Announce Strategic Collaboration to Advance Novel Rapid Diagnostic Tests for Tropical Diseases Read More »

Zalgen Labs Introduces Viral Diagnostics Business, Opens Advanced Product Development Center in Colorado

Zalgen Labs, a biotechnology and diagnostics company focused on high-impact, neglected infectious diseases, announced that it has received via transfer the viral hemorrhagic fever diagnostics business from Corgenix Medical Corporation and opened an advanced product development center in the Fitzsimons Bioscience Park Center on the University of Colorado Anschutz Medical Campus in Aurora, Colo. Zalgen

Zalgen Labs Introduces Viral Diagnostics Business, Opens Advanced Product Development Center in Colorado Read More »

Shopping Cart
Scroll to Top